US 11,685,932 B2
Inducible AAV Rep genes
Kerstin Hein, Cologne (DE); Nicole Faust, Cologne (DE); and Silke Wissing, Cologne (DE)
Assigned to Cevec Pharmaceuticals, GmbH, Cologne (DE)
Appl. No. 16/646,741
Filed by Cevec Pharmaceuticals, GmbH, Cologne (DE)
PCT Filed Sep. 18, 2018, PCT No. PCT/EP2018/075158
§ 371(c)(1), (2) Date Mar. 12, 2020,
PCT Pub. No. WO2019/057691, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 17001562 (EP), filed on Sep. 19, 2017.
Prior Publication US 2020/0277628 A1, Sep. 3, 2020
Int. Cl. C12N 15/86 (2006.01); C12N 15/01 (2006.01); C12N 15/63 (2006.01)
CPC C12N 15/86 (2013.01) [C12N 15/01 (2013.01); C12N 15/63 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14152 (2013.01)] 10 Claims
 
1. An isolated host cell comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68 operably linked to an inducible promoter, wherein the internal AAV promoter p19 comprises a substitution at position 818 from a guanine to an adenine wherein the position 818 is numbered according to a complete AAV2 genome of GenBank Accession number AF043303, whereby the internal AAV promoter p19 is inactivated and the functionality of said Rep78 and Rep68 proteins is maintained.